MiNK Therapeutics, Inc.
INKT
$11.90
$0.453.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.09% | 32.01% | 117.99% | 58.77% | 74.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -298.51% | 7.19% | -- |
| Total Operating Expenses | -20.62% | 13.78% | 8.10% | 68.93% | 39.66% |
| Operating Income | 20.62% | -13.78% | -8.10% | -68.93% | -39.66% |
| Income Before Tax | 26.18% | 0.88% | -5.64% | -59.84% | -56.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.18% | 0.88% | -5.64% | -59.84% | -56.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.18% | 0.88% | -5.64% | -59.84% | -56.85% |
| EBIT | 20.62% | -13.78% | -8.10% | -68.93% | -39.66% |
| EBITDA | 20.55% | -14.65% | -8.91% | -72.33% | -40.15% |
| EPS Basic | 41.49% | 18.09% | 10.81% | -42.21% | -46.30% |
| Normalized Basic EPS | 41.48% | 12.79% | 10.80% | -42.23% | -45.44% |
| EPS Diluted | 41.49% | 18.09% | 10.81% | -42.21% | -46.30% |
| Normalized Diluted EPS | 41.48% | 12.79% | 10.80% | -42.23% | -45.44% |
| Average Basic Shares Outstanding | 26.16% | 21.00% | 18.43% | 12.39% | 7.21% |
| Average Diluted Shares Outstanding | 26.16% | 21.00% | 18.43% | 12.39% | 7.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |